Title

Study to Assess the Benefit of Midodrine in the Treatment of Patients With Neurogenic Orthostatic Hypotension
A Multi-Center, Double-Blind, Randomized, Placebo-controlled, Crossover Study to Assess the Clinical Benefit of Midodrine Hydrochloride in Subjects With Moderate to Severe Neurogenic Orthostatic Hypotension
  • Phase

    Phase 4
  • Study Type

    Interventional
  • Intervention/Treatment

    midodrine ...
  • Study Participants

    24
The purpose of this clinical study is to evaluate the clinical effect of midodrine hydrochloride (ProAmatine®) compared to placebo in patients with orthostatic hypotension by measuring the time to onset of near syncopal symptoms and assessing several cardiovascular measurements, such as heart rate, blood pressure, and ECG, using the tilt table test.
Study Started
Sep 08
2004
Primary Completion
Mar 21
2005
Study Completion
Mar 21
2005
Results Posted
May 21
2015
Estimate
Last Update
Jun 14
2021

Drug Midodrine hydrochloride

one dose, 10-30mg, given orally

  • Other names: ProAmatine

Drug Placebo

Placebo

1 Experimental

2 Placebo Comparator

Criteria

Inclusion Criteria:

The male or female subjects must be 18 years of age or older and ambulatory. (Subjects must not require assistance with a walker or wheelchair to perform regular daily activities at all times.)
Women of childbearing potential must have a negative serum beta HCG pregnancy test at screening and baseline.
The subject has been diagnosed with symptomatic orthostatic hypotension due to Parkinson's disease, multiple system atrophy, pure autonomic failure or autonomic neuropathy (i.e. neurogenic orthostatic hypotension).
The subject manifests one of the following symptoms while standing or has a history of one of the following when not treated for orthostatic hypotension: dizziness, lightheadedness, feeling faint or feeling like they may black out.
The subject is willing and able to undergo the procedures required by this protocol including morning office visits, assessment completion, protocol compliance and participation in the wash-out period.
The subject has signed an Institutional-Review-Board approved written informed consent form prior to any study procedures taking place.

Exclusion Criteria:

The subject is a pregnant or lactating female.
The subject has pre-existing sustained supine hypertension greater than 180 mm Hg systolic and 110 mm Hg diastolic.
The subject is taking medications such as vasodilators, pressors, diuretics, ACE inhibitors, angiotensin receptor blockers, beta-blockers, combined alpha and beta-blockers, MAOI's, herbals or specific mixed effect medications.
The Principal Investigator deems any laboratory test abnormality clinical significant.
The subject has a diagnosis of any of the following disorders at the time of screening: pheochromocytoma; cardiac conditions including: congestive heart failure within the previous 6 months, myocardial infarction within the previous 6 months, symptomatic coronary artery disease, history of ventricular tachycardia, or uncontrolled cardiac arrhythmias; thyrotoxicosis; uncontrolled diabetes mellitus (uncontrolled defined as a HgbA1c greater than or equal to 10%); history of cerebrovascular accident, transient ischemic attack (TIA) or symptomatic carotid artery stenosis within the previous 6 months; history of coagulopathies; pulmonary hypertension; severe psychiatric disorders; renal failure (Creatinine equal to or greater than 2 times the upper limit of normal)
The subject has a concurrent chronic or acute illness, disability, or other condition that might confound the results of the tests and/or measurements administered in this trial, or that might increase the risk to the subject.

Summary

Midodrine/Placebo

Placebo/Midodrine

All Events

Event Type Organ System Event Term Midodrine/Placebo Placebo/Midodrine

Time to Onset of Near-syncopal Symptoms During Tilt Table Testing Analysis #2

The tilt table test is a 10-minute assessment performed using a manual or automated tilt table in a specialized laboratory. Subjects were moved onto the horizontal table and secured to the table with straps to prevent injury. After an equilibration period of at least 10 minutes with the subject at rest, the test began and the head of the tilt table was elevated to a 70-degree angle over a period of up to 30 seconds. The head-up tilt table test in this study was conducted 1 hour after administration of the study medication. The endpoint was a confirmed report of a near- syncopal symptom(s) (of sufficient severity that caused the patient to ask that the tilt table be returned to the horizontal position). Symptoms of near syncope were defined as dizziness, lightheadedness, feeling faint, or feeling like the subject might black out. In this outcome measure, the data analyzed are the same as for Outcome Measure 1 but the summary data are presented as least squares mean (standard error).

Midodrine HCl

552.4
seconds (Least Squares Mean)
Standard Error: 32.93

Placebo

460.0
seconds (Least Squares Mean)
Standard Error: 32.93

Time to Onset of Near-syncopal Symptoms During Tilt Table Testing-Re-analysis With The Koch Procedure

The tilt table test is a 10-minute assessment performed using a manual or automated tilt table in a specialized laboratory. Subjects were moved onto the horizontal table and secured to the table with straps to prevent injury. After an equilibration period of at least 10 minutes with the subject at rest, the test began and the head of the tilt table was elevated to a 70-degree angle over a period of up to 30 seconds. The head-up tilt table test in this study was conducted 1 hour after administration of the study medication. The endpoint was a confirmed report of a near-syncopal symptom(s) (of sufficient severity that caused the patient to ask that the tilt table be returned to the horizontal position). Symptoms of near syncope were defined as dizziness, lightheadedness, feeling faint, or feeling like the subject might black out. The Koch procedure is a 3-step process to analyze results while utilizing the available information on magnitude of differences.

Midodrine HCl

551.3
seconds (Mean)
Standard Deviation: 115.63

Placebo

461.0
seconds (Mean)
Standard Deviation: 190.74

Time to Onset of Near-syncopal Symptoms During Tilt Table Testing

The tilt table test is a 10-minute assessment performed using a manual or automated tilt table in a specialized laboratory. Subjects were moved onto the horizontal table and secured to the table with straps to prevent injury. After an equilibration period of at least 10 minutes with the subject at rest, the test began and the head of the tilt table was elevated to a 70-degree angle over a period of up to 30 seconds. The head-up tilt table test in this study was conducted 1 hour after administration of the study medication. The endpoint was a confirmed report of a near-syncopal symptom(s) (of sufficient severity that caused the patient to ask that the tilt table be returned to the horizontal position). Symptoms of near syncope were defined as dizziness, lightheadedness, feeling faint, or feeling like the subject might black out.

Midodrine HCl

551.3
seconds (Mean)
Standard Deviation: 115.63

Placebo

461.0
seconds (Mean)
Standard Deviation: 190.74

Time to Near-syncopal Symptoms at Treatment Visit 1

The tilt table test is a 10-minute assessment performed using a manual or automated tilt table in a specialized laboratory. Subjects were moved onto the horizontal table and secured to the table with straps to prevent injury. After an equilibration period of at least 10 minutes with the subject at rest, the test began and the head of the tilt table was elevated to a 70-degree angle over a period of up to 30 seconds. The head-up tilt table test in this study was conducted 1 hour after administration of the study medication. The endpoint was a confirmed report of a near-syncopal symptom(s) (of sufficient severity that caused the patient to ask that the tilt table be returned to the horizontal position). Symptoms of near syncope were defined as dizziness, lightheadedness, feeling faint, or feeling like the subject might black out.

Midodrine HCl

539.5
seconds (Least Squares Mean)
Standard Error: 45.91

Placebo

448.4
seconds (Least Squares Mean)
Standard Error: 49.91

Duration of The Effect of Treatment at 3 Hours Post-dose

Duration of effect was defined as the difference in time to onset of near-syncopal symptoms between the first and second tilt table test, conducted at 1 hour and 3 hours post-dose, respectively, at Treatment Visit 2 (time to onset at 3 hours minus time at 1 hour). The tilt table test is a 10-minute assessment performed using a manual or automated tilt table in a specialized laboratory. Subjects were moved onto the horizontal table and secured to the table with straps to prevent injury. After an equilibration period of at least 10 minutes with the subject at rest, the test began and the head of the tilt table was elevated to a 70-degree angle over a period of up to 30 seconds. The endpoint was a confirmed report of a near-syncopal symptom(s) (of sufficient severity that caused the patient to ask that the tilt table be returned to the horizontal position). Symptoms of near syncope were defined as dizziness, lightheadedness, feeling faint, or feeling like the subject might black out.

Midodrine HCl

45.1
seconds (Mean)
Standard Deviation: 94.03

Placebo

48.0
seconds (Mean)
Standard Deviation: 114.96

Total Score of the Orthostatic Hypotension Symptom Assessment (OHSA)

The OHSA measures the severity of six symptoms/symptom complexes associated with orthostatic hypotension. Subjects rated symptoms experienced during the tilt table test on an eleven-point scale from "none" to "worst possible". The OHSA total score is the sum of six subscales, ranging from 0 (no symptoms) to 60 (worst possible symptoms). The OHSA was completed after the tilt table test was over, but was answered with reference to symptoms experienced during testing. The tilt table test is a 10-minute assessment performed using a manual or automated tilt table in a specialized laboratory. Subjects were moved onto the horizontal table and secured to the table with straps to prevent injury. After an equilibration period with the subject at rest, the test began and the head of the tilt table was elevated to a 70-degree angle over a period of up to 30 seconds. Symptoms of near syncope were defined as dizziness, lightheadedness, feeling faint, or feeling like the subject might black out.

Midodrine HCl

13.7
scores on a scale (Least Squares Mean)
Standard Error: 2.95

Placebo

19.4
scores on a scale (Least Squares Mean)
Standard Error: 2.95

Scores for 6 Items of The OHSA

The OHSA measures the severity of six symptoms/symptom complexes associated with OH: dizziness, lightheadedness, and feeling faint; problems with vision; weakness; fatigue; trouble concentrating; and head/neck discomfort. Subjects rated symptoms experienced during the tilt table test on an eleven-point scale from "none" to "worst possible". Scores for each subscale range from 0 (no symptoms) to 10 (worst possible symptoms). The OHSA was completed after the tilt table test was over, but was answered with reference to symptoms experienced during testing. The tilt table test is a 10-minute assessment performed using a tilt table in a specialized laboratory. Subjects were moved onto the horizontal table and secured with straps to prevent injury. After an equilibration period with the subject at rest, the test began and the head of the tilt table was elevated to a 70-degree angle over 30 seconds. Symptoms of near syncope were defined as dizziness, lightheadedness, and feeling faint.

Midodrine HCl

Dizziness, Lightheadedness, and Feeling Faint

3.4
scores on a scale (Mean)
Standard Deviation: 3.44

Fatigue

2.7
scores on a scale (Mean)
Standard Deviation: 3.22

Head/Neck Discomfort

1.9
scores on a scale (Mean)
Standard Deviation: 2.52

Problems with Vision

1.5
scores on a scale (Mean)
Standard Deviation: 2.32

Trouble Concentrating

1.7
scores on a scale (Mean)
Standard Deviation: 2.04

Weakness

3.0
scores on a scale (Mean)
Standard Deviation: 3.13

Placebo

Dizziness, Lightheadedness, and Feeling Faint

4.7
scores on a scale (Mean)
Standard Deviation: 3.57

Fatigue

3.5
scores on a scale (Mean)
Standard Deviation: 3.48

Head/Neck Discomfort

2.1
scores on a scale (Mean)
Standard Deviation: 3.21

Problems with Vision

2.7
scores on a scale (Mean)
Standard Deviation: 3.43

Trouble Concentrating

2.6
scores on a scale (Mean)
Standard Deviation: 3.13

Weakness

4.1
scores on a scale (Mean)
Standard Deviation: 3.17

Number of Participants With Improvement of Clinician Clinician's Global Impression- Improvement (CGI-I) Scores After Tilt Table Test

The CGI-I instrument assesses the overall impression of the subject's orthostatic hypotension during the tilt table test by using a 7-point scale, with 1 being Very much improved; 2, Much improved; 3, Slightly improved; 4, No change; 5, Slightly worse; 6, Much worse; and 7, Very much worse. The clinician completed the CGI-I after each of the tilt table tests. A patient was assessed as "Improved" if the score was 1, 2, or 3. The tilt table test is a 10-minute assessment performed using a manual or automated tilt table in a specialized laboratory. Subjects were moved onto the horizontal table and secured to the table with straps to prevent injury. After an equilibration period of at least 10 minutes with the subject at rest, the test began and the head of the tilt table was elevated to a 70-degree angle over a period of up to 30 seconds. Symptoms of near syncope were defined as dizziness, lightheadedness, feeling faint, or feeling like the subject might black out.

Midodrine HCl

Treatment Visit 1- 1 hour post-dose, n=13, 11

4.0
participants

Treatment Visit 2- 1 hour post-dose, n=11, 13

6.0
participants

Treatment Visit 2- 3 hour post-dose, n= 11, 12

3.0
participants

Placebo

Treatment Visit 1- 1 hour post-dose, n=13, 11

4.0
participants

Treatment Visit 2- 1 hour post-dose, n=11, 13

4.0
participants

Treatment Visit 2- 3 hour post-dose, n= 11, 12

5.0
participants

Number of Participants With Improvement of Patient CGI-I Scores After Tilt Table Test

The CGI-I instrument assesses the overall impression of the subject's orthostatic hypotension during the tilt table test by using a 7-point scale, with 1 being Very much improved; 2, Much improved; 3, Slightly improved; 4, No change; 5, Slightly worse; 6, Much worse; and 7, Very much worse. The patient completed the CGI-I after each of the tilt table tests. A patient was assessed as "Improved" if the score was 1, 2, or 3. The tilt table test is a 10-minute assessment performed using a manual or automated tilt table in a specialized laboratory. Subjects were moved onto the horizontal table and secured to the table with straps to prevent injury. After an equilibration period of at least 10 minutes with the subject at rest, the test began and the head of the tilt table was elevated to a 70-degree angle over a period of up to 30 seconds. Symptoms of near syncope were defined as dizziness, lightheadedness, feeling faint, or feeling like the subject might black out.

Midodrine HCl

Treatment Visit 1-1 hour post-dose, n= 13, 11

3.0
participants

Treatment Visit 2-1 hour post-dose, n= 11, 13

5.0
participants

Treatment Visit 2-3 hour post-dose, n= 11, 12

3.0
participants

Placebo

Treatment Visit 1-1 hour post-dose, n= 13, 11

2.0
participants

Treatment Visit 2-1 hour post-dose, n= 11, 13

3.0
participants

Treatment Visit 2-3 hour post-dose, n= 11, 12

3.0
participants

Final Blood Pressure During Tilt Table Testing

Blood pressure was recorded just before tilt table testing and immediately after. Timed readings were stopped once a subject experienced near-syncopal symptoms, except for subjects for whom the table was returned to horizontal before 1 minute; for these subjects, a reading was made at 1 minute and was included in analyses. The tilt table test is a 10-minute assessment performed using a manual or automated tilt table in a specialized laboratory. Subjects were moved onto the horizontal table and secured to the table with straps to prevent injury. After an equilibration period of at least 10 minutes with the subject at rest, the test began and the head of the tilt table was elevated to a 70-degree angle over a period of up to 30 seconds. Symptoms of near syncope were defined as dizziness, lightheadedness, feeling faint, or feeling like the subject might black out.

Midodrine HCl

Diastolic Pressure

70.6
mmHg (Mean)
Standard Deviation: 16.44

Systolic Pressure

106.5
mmHg (Mean)
Standard Deviation: 37.27

Placebo

Diastolic Pressure

60.6
mmHg (Mean)
Standard Deviation: 15.04

Systolic Pressure

90.2
mmHg (Mean)
Standard Deviation: 24.17

Systolic Blood Pressure at 1 Minute and 10 Minutes Into The Tilt Table Test Conducted 1 and 3 Hours Post-dose at Treatment Visit 2

Blood pressure was recorded just before tilt table testing, at each minute during tilt table testing, and immediately after. Timed readings were stopped once a subject experienced near-syncopal symptoms, except for subjects for whom the table was returned to horizontal before 1 minute; for these subjects, a reading was made at 1 minute and was included in analyses. The tilt table test is a 10-minute assessment performed using a manual or automated tilt table in a specialized laboratory. Subjects were moved onto the horizontal table and secured to the table with straps to prevent injury. After an equilibration period of at least 10 minutes with the subject at rest, the test began and the head of the tilt table was elevated to a 70-degree angle over a period of up to 30 seconds. Symptoms of near syncope were defined as dizziness, lightheadedness, feeling faint, or feeling like the subject might black out.

Midodrine HCl

At 10 minutes 1 hour post-dose, n= 10, 8

121.7
mmHg (Mean)
Standard Deviation: 37.57

At 10 minutes 3 hours post-dose, n= 7, 6

108.3
mmHg (Mean)
Standard Deviation: 30.48

At 1 minute 1 hour post-dose, n= 11, 13

142.2
mmHg (Mean)
Standard Deviation: 44.20

At 1 minute 3 hours post-dose, n= 11, 12

110.1
mmHg (Mean)
Standard Deviation: 19.06

Placebo

At 10 minutes 1 hour post-dose, n= 10, 8

102.9
mmHg (Mean)
Standard Deviation: 21.03

At 10 minutes 3 hours post-dose, n= 7, 6

107.2
mmHg (Mean)
Standard Deviation: 19.32

At 1 minute 1 hour post-dose, n= 11, 13

97.3
mmHg (Mean)
Standard Deviation: 24.55

At 1 minute 3 hours post-dose, n= 11, 12

94.9
mmHg (Mean)
Standard Deviation: 31.36

Diastolic Blood Pressure at 1 Minute and 10 Minutes Into The Tilt Table Test Conducted 1 and 3 Hours Post-dose at Treatment Visit 2

Blood pressure was recorded just before tilt table testing, at each minute during tilt table testing, and immediately after. Timed readings were stopped once a subject experienced near-syncopal symptoms, except for subjects for whom the table was returned to horizontal before 1 minute; for these subjects, a reading was made at 1 minute and was included in analyses. The tilt table test is a 10-minute assessment performed using a manual or automated tilt table in a specialized laboratory. Subjects were moved onto the horizontal table and secured to the table with straps to prevent injury. After an equilibration period of at least 10 minutes with the subject at rest, the test began and the head of the tilt table was elevated to a 70-degree angle over a period of up to 30 seconds. Symptoms of near syncope were defined as dizziness, lightheadedness, feeling faint, or feeling like the subject might black out.

Midodrine HCl

At 10 minutes 1 hour post-dose, n= 10, 8

79.6
mmHg (Mean)
Standard Deviation: 16.18

At 10 minutes 3 hours post-dose, n= 7, 6

69.3
mmHg (Mean)
Standard Deviation: 13.55

At 1 minute 1 hour post-dose, n= 11, 12

81.5
mmHg (Mean)
Standard Deviation: 19.09

At 1 minute 3 hours post-dose, n= 11, 12

66.1
mmHg (Mean)
Standard Deviation: 9.66

Placebo

At 10 minutes 1 hour post-dose, n= 10, 8

64.9
mmHg (Mean)
Standard Deviation: 11.22

At 10 minutes 3 hours post-dose, n= 7, 6

60.7
mmHg (Mean)
Standard Deviation: 14.69

At 1 minute 1 hour post-dose, n= 11, 12

60.8
mmHg (Mean)
Standard Deviation: 13.99

At 1 minute 3 hours post-dose, n= 11, 12

60.3
mmHg (Mean)
Standard Deviation: 18.53

Heart Rate at 1 Minute and 10 Minutes Into The Tilt Table Test Conducted 1 and 3 Hours Post-dose at Treatment Visit 2

Heart rate was recorded just before tilt table testing, at each minute during tilt table testing, and immediately after. Timed readings were stopped once a subject experienced near-syncopal symptoms, except for subjects for whom the table was returned to horizontal before 1 minute; for these subjects, a reading was made at 1 minute and was included in analyses. The tilt table test is a 10-minute assessment performed using a manual or automated tilt table in a specialized laboratory. Subjects were moved onto the horizontal table and secured to the table with straps to prevent injury. After an equilibration period of at least 10 minutes with the subject at rest, the test began and the head of the tilt table was elevated to a 70-degree angle over a period of up to 30 seconds. Symptoms of near syncope were defined as dizziness, lightheadedness, feeling faint, or feeling like the subject might black out.

Midodrine HCl

At 10 minutes 1 hour post-dose, n= 10, 8

77.7
beats per minute (Mean)
Standard Deviation: 16.08

At 10 minutes 3 hours post-dose, n= 8, 6

80.9
beats per minute (Mean)
Standard Deviation: 11.66

At 1 minute 1 hour post-dose, n= 11, 13

77.6
beats per minute (Mean)
Standard Deviation: 13.93

At 1 minute 3 hours post-dose, n= 11, 12

79.7
beats per minute (Mean)
Standard Deviation: 11.30

Placebo

At 10 minutes 1 hour post-dose, n= 10, 8

79.5
beats per minute (Mean)
Standard Deviation: 16.48

At 10 minutes 3 hours post-dose, n= 8, 6

81.3
beats per minute (Mean)
Standard Deviation: 20.16

At 1 minute 1 hour post-dose, n= 11, 13

80.5
beats per minute (Mean)
Standard Deviation: 14.07

At 1 minute 3 hours post-dose, n= 11, 12

80.9
beats per minute (Mean)
Standard Deviation: 13.19

Number of Participants With Shifts in Reference to Normal Range For Hematology Analytes at Discharge

For hematology, blood samples (5.0mL) were taken at screening, study admission (if greater than 14 days since screening) and discharge/early termination. The following parameters were assessed: hemoglobin, hematocrit, red blood cells (RBC), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), white blood cell count - total and differential (WBC), and platelet count. A shift in reference to normal was either lower or higher at discharge.

All Participants

Hematocrit

Hemoglobin

1.0
participants

MCH

MCHC

2.0
participants

MCV

Platelet count

RBC

WBC

1.0
participants

Number of Participants With Shifts in Reference to Normal Range For Clinical Chemistry at Discharge

For biochemistry, blood samples (10.0mL) were taken at screening, admission (if greater than 14 days since screening) and discharge/early termination. The following parameters were assessed: sodium, potassium, calcium, blood urea nitrogen (BUN)/Urea, creatinine, albumin, total protein and albumin/globulin (A/G) ratio, globulin, aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP), gamma glutamyl transferase (GGT), total bilirubin, glucose, chloride, and creatine kinase. A shift in reference to normal was either lower or higher at discharge.

All Participants

Albumin

ALP

1.0
participants

ALT

AST

BUN/Urea

Calcium

1.0
participants

Chloride

Creatine kinase

1.0
participants

Creatinine

1.0
participants

GGT

Globulin

Glucose

6.0
participants

Potassium

2.0
participants

Sodium

Total bilirubin

1.0
participants

Total protein and A/G ratio

2.0
participants

Number of Participants With Shifts in Reference to Normal Range For Urinalysis at Discharge

For urinalysis, samples were taken at screening, study admission (if greater than 14 days since screening) and discharge/early termination): glucose, blood, protein, pH, specific gravity, leukocyte esterase, and microscopic examination. A shift in reference to normal was higher at discharge.

All Participants

Blood

2.0
participants

Glucose

1.0
participants

Leukocyte esterase

2.0
participants

Microscopic examination

pH

Protein

Specific gravity

Time to Onset of Near-syncopal Symptoms in The Per-protocol Population

The tilt table test is a 10-minute assessment performed using a manual or automated tilt table in a specialized laboratory. Subjects were moved onto the horizontal table and secured to the table with straps to prevent injury. After an equilibration period of at least 10 minutes with the subject at rest, the test began and the head of the tilt table was elevated to a 70-degree angle over a period of up to 30 seconds. The head-up tilt table test in this study was conducted 1 hour after administration of the study medication. The endpoint was a confirmed report of a near-syncopal symptom(s) (of sufficient severity that caused the patient to ask that the tilt table be returned to the horizontal position). Symptoms of near syncope were defined as dizziness, lightheadedness, feeling faint, or feeling like the subject might black out.

Midodrine HCl

544.3
seconds (Mean)
Standard Deviation: 122.34

Placebo

447.9
seconds (Mean)
Standard Deviation: 199.31

Time to Onset of Near-syncopal Symptoms in The Per-protocol Population Analysis #2

The tilt table test is a 10-minute assessment performed using a manual or automated tilt table in a specialized laboratory. Subjects were moved onto the horizontal table and secured to the table with straps to prevent injury. After an equilibration period of at least 10 minutes with the subject at rest, the test began and the head of the tilt table was elevated to a 70-degree angle over a period of up to 30 seconds. The head-up tilt table test in this study was conducted 1 hour after administration of the study medication. The endpoint was a confirmed report of a near- syncopal symptom(s) (of sufficient severity that caused the patient to ask that the tilt table be returned to the horizontal position). Symptoms of near syncope were defined as dizziness, lightheadedness, feeling faint, or feeling like the subject might black out. In this outcome measure, the data analyzed are the same as for Outcome Measure 4 but the summary data are presented as least squares mean (standard error).

Midodrine HCl

545.1
seconds (Least Squares Mean)
Standard Error: 36.90

Placebo

447.2
seconds (Least Squares Mean)
Standard Error: 36.90

Total

24
Participants

Age, Continuous

60.0
years (Mean)
Standard Deviation: 15.46

Ethnicity (NIH/OMB)

Race (NIH/OMB)

Sex: Female, Male

Treatment Period 1 (1 Day)

Midodrine/Placebo

Placebo/Midodrine

Washout (1 Day)

Midodrine/Placebo

Placebo/Midodrine

Treatment Period 2 (1 Day)

Midodrine/Placebo

Placebo/Midodrine